Accolade (ACCD) Stock Price, News & Analysis

Company Overview

Accolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and primary care physicians. It also provides medical opinion services to commercial customers; and navigation, care, and advocacy solutions. In addition, the company offers medical consultations that connect patients to qualified condition-specific specialists for adult and pediatric care; and primary care and mental health support solutions. It serves employers who provide employees and their families a single place to turn for their health, healthcare, and benefits needs. The company was incorporated in 2007 and is headquartered in Seattle, Washington.

Key Stats

• Today's Range: $3.52 to $3.73
• 50-Day Range: $3.15 to $4.31
• 52-Week Range: $3.08 to $15.36
• Volume: 1.63 million shs
• Average Volume: 1.10 million shs
• Market Capitalization: $300.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.04
• Consensus Rating: Moderate Buy

Accolade Stock Analysis - MarketRank™

Accolade scored higher than 97% of companies evaluated by MarketBeat, and ranked 15th out of 323 stocks in the business services sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Accolade has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 12 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Accolade has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Accolade are expected to grow in the coming year, from ($0.92) to ($0.87) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Accolade is -3.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Accolade is -3.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Accolade has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.03% of the outstanding shares of Accolade have been sold short.

Short Interest Ratio / Days to Cover

Accolade has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Accolade has recently decreased by 5.26%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Accolade does not currently pay a dividend.

Dividend Growth

Accolade does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.8 / 5
• Environmental Score: -0.89

Percentage of Shares Shorted

6.03% of the outstanding shares of Accolade have been sold short.

Short Interest Ratio / Days to Cover

Accolade has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Accolade has recently decreased by 5.26%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: 0.13

News Sentiment

Accolade has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Business Services companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Accolade this week, compared to 3 articles on an average week.

Search Interest

Only 3 people have searched for ACCD on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Accolade to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Accolade insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $55,827.00 in company stock.

Percentage Held by Insiders

Only 8.20% of the stock of Accolade is held by insiders.

Percentage Held by Institutions

84.99% of the stock of Accolade is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ACCD Stock Analysis - Frequently Asked Questions

How have ACCD shares performed this year?

Accolade's stock was trading at $12.01 on January 1st, 2024. Since then, ACCD shares have decreased by 69.0% and is now trading at $3.7290.
View the best growth stocks for 2024 here.

How were Accolade's earnings last quarter?

Accolade, Inc. (NASDAQ:ACCD) announced its quarterly earnings results on Tuesday, October, 8th. The company reported ($0.30) EPS for the quarter, topping analysts' consensus estimates of ($0.44) by $0.14. Accolade's revenue was up 9.8% compared to the same quarter last year.

When did Accolade IPO?

Accolade (ACCD) raised $176 million in an initial public offering (IPO) on Thursday, July 2nd 2020. The company issued 8,800,000 shares at a price of $19.00-$21.00 per share. Goldman Sachs, Morgan Stanley and BofA Securities served as the underwriters for the IPO and Piper Sandler, Credit Suisse, William Blair, Baird and SVB Leerink were co-managers.

Who are Accolade's major shareholders?

Accolade's top institutional shareholders include ARK Investment Management LLC (6.68%), State Street Corp (2.39%), Sumitomo Mitsui Trust Group Inc. (2.35%) and Geode Capital Management LLC (2.21%). Insiders that own company stock include Stephen H Barnes, Robert N Cavanaugh, Michael W Hilton, Colin Mchugh and Richard Eskew.
View institutional ownership trends.

How do I buy shares of Accolade?

Shares of ACCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Accolade own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Accolade investors own include American Water Works (AWK), Waste Connections (WCN), AUO (AUOTY), DiamondRock Hospitality (DRH), Humana (HUM), The RMR Group (RMR) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 10/08/2024
• Today: 11/21/2024
• Next Earnings (Estimated): 1/13/2025
• Fiscal Year End: 2/28/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Business Services
• Industry: Business services, not elsewhere classified
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:ACCD
• CUSIP: N/A
• CIK: 1481646
• Web: accolade.com
• Phone: 206-926-8100
• Fax: N/A
• Employees: 2,400
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $9.04
• High Stock Price Target: $16.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +142.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 15 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-99,810,000.00
• Net Margins: -18.16%
• Pretax Margin: -17.76%
• Return on Equity: -18.43%
• Return on Assets: -10.35%

Debt

• Debt-to-Equity Ratio: 0.49
• Current Ratio: 2.72
• Quick Ratio: 2.72

Sales & Book Value

• Annual Sales: $414.29 million
• Price / Sales: 0.72
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.75 per share
• Price / Book: 0.65

Miscellaneous

• Outstanding Shares: 80,540,000
• Free Float: 73,933,000
• Market Cap: $300.33 million
• Optionable: Optionable
• Beta: 2.02